USBC insider granted 1.96M options at $1.10; total 3.75M
Rhea-AI Filing Summary
USBC, Inc. reporting person Kitty B. Payne, who serves as CFO/Treasurer/Secretary and a director, disclosed option activity on 10/07/2025. The Board approved a repricing that reduced the exercise price on 1,790,000 outstanding options from $2.45 to $1.10. The reporting person also received a new grant of 1,960,000 options exercisable at $1.10. After these transactions the reporting person beneficially owns 3,750,000 underlying shares via options, all exercisable through 2035 with standard vesting of 25% after one year and quarterly installments over three years thereafter.
The repricing and new grant increase the reporting persons option exposure and lower near-term strike prices, which may affect dilution and align executive incentives with current share value. All terms disclosed are pursuant to the Amended and Restated 2021 Equity Incentive Plan.
Positive
- Significant retention feature: options vest over 4-year schedule with 25% cliff, encouraging long-term retention
- Lower exercise price to $1.10 may improve upside alignment between executive pay and shareholder returns if stock recovers
Negative
- Potential dilution: reporting person now holds options for 3,750,000 shares, which could dilute existing shareholders upon exercise
- Repricing governance concern: post-grant repricing can be viewed negatively by investors as altering original award economics
Insights
Repricing lowers strike and extends incentive exposure to align pay with current valuation.
The Board reduced the exercise price on 1,790,000 options to $1.10, and granted an additional 1,960,000 options at the same price, increasing the reporting persons total underlying options to 3,750,000. Vesting is standard: 25% after one year then quarterly over three years, which phases retention over a multi-year period.
This structure increases potential upside for the officer if the stock rises, while also creating near-term dilution risk; monitor option exercise behavior, outstanding option run-rate, and share-count changes over the next 12-36 months for dilution impact.
Board-approved repricing is a material governance action with stakeholder implications.
The Boards approval to reprice options originally granted on 08/06/2025 indicates an explicit decision to adjust executive economics after grant. Repricing can be permissible under the equity plan but may raise shareholder governance questions about alignment and timing.
Investors should note the 10/07/2025 approval date and the 2035 expiration terms; review the equity plan's repricing policies and any shareholder approvals or disclosures in periodic filings within the next filing cycle.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Option to Purchase Common Stock | 1,790,000 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 1,790,000 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 1,960,000 | $0.00 | -- |
Footnotes (1)
- The transactions reported involved the repricing of outstanding stock options to purchase 1,790,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), initially granted on August 6, 2025 (the "Grant Date"). The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years. On October 7, 2025, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted on August 6, 2025. The exercise price of each repriced option was reduced from $2.45 to $1.10 per share. On October 7, 2025, the Reporting Person was granted an option to purchase 1,960,000 shares of the Company's common stock pursuant to the Amended and Restated 2021 Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.
